ReWing

ReWing operates at the intersection of rehabilitation robotics, medical devices, and clinical research. Its stated focus is sensorimotor rehabilitation for people with orthopedic and neurological impairments, while its EDUSA product line also targets research in motor control, motor learning, rehabilitation, and ergonomics. The Edusa PRO-r differentiates its offering through wrist and forearm instrumentation, multiple exercise modes, customizable protocols, and synchronization with external devices such as EMG and EEG systems. The company is private, has disclosed a pre-seed round in July 2022 and a seed round in May 2023, and has a reported employee band of 1–10. These indicators place it at an early stage relative to established medical-device businesses, with a focused technical niche but limited publicly documented scale.

ReWing’s visible financing history shows an early-stage progression: a pre-seed round in July 2022, followed by a seed round in May 2023. RoboIT appears as a lead investor in both rounds; Pariter Partners is named in the pre-seed round and Pariter Robotics in the seed round. The amounts are undisclosed, preventing assessment of capital raised, runway, or the size of the step-up between rounds. Product development provides a second indicator of trajectory. Edusa PRO-r is described as a research-oriented robotic system for wrist and forearm movement, while ReWing AI software supports customizable exercises and adaptive assistance. The platform’s stated technical features include four operating modes, high-resolution movement measurement, real-time acquisition at 1 kHz, and data synchronization with external devices. Overall, the funding sequence and specialized product capabilities suggest development from an early research-driven venture toward clinical and research applications, but evidence of subsequent financing, regulatory milestones, or scaled deployment is limited.